



Personalized Medicine in Spondyloarthritis

Guest Editor:

Prof. Dr. Codrina Ancuta
Rheumatology Department,
University of Medicine and
Pharmacy “Grigore T Popa”,
700115 Iasi, Romania

Deadline for manuscript
submissions:


15 March 2024

Message from the Guest Editor

Important advances in the understanding of SpA have been made in the area of classification criteria, significantly improving the approach to these diseases and the identification of patients in early stages of the disease. Numerous studies have elucidated the immune mechanisms underlying specific clinical manifestations of the disease, opening the way to new and more personalized therapeutic approaches. In particular, new and more specific treatments promise to make feasible treat-to-target and drug-free remission in SpA, which were once impossible objectives. Although the diagnostic delay in SpA is still considerable, the increased awareness and insights into diagnosis at early stages of the disease are contributing to improving its management.

The present Special Issue aims to deepen the knowledge of SpA from bench to bedside, providing a broad update on the pathophysiological, diagnostic, and therapeutic aspects of the disease.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Senior Vice President and Director, Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Professor of Medicine Chief, Section of Hematologic Malignancies, Associate Director for Clinical Research, Division of Hematologic Malignancies and Cellular Therapy Duke Cancer Institute, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[@JPM_MDPI](https://twitter.com/JPM_MDPI)